2022_Stevanato_Aidaptus_Leaderboard

Resyca

Resyca, a joint venture between Recipharm and Medspray, develops next-generation soft mist inhalers, including prefilled syringes inhalers, for the delivery of both small and large molecules, and designed to optimise lung deposition whilst minimising oropharyngeal deposition.




Associated Companies

  Recipharm     Medspray  

HEADQUARTERS
Resyca BV
Colosseum 23
7521 PV Enschede
The Netherlands

Resyca develops next-generation soft mist inhalers for the delivery of both small and large molecules, and designed to optimise lung deposition whilst minimising oropharyngeal deposition.

Resyca is a joint venture between Recipharm and Medspray, and a sister company to Recipharm, forming part of Recipharm’s Advanced Delivery Systems business unit.

Resyca’s soft mist inhaler platform consists of both prefilled syringes inhalers and clinical trial devices that can be filled on the spot, speeding up clinical investigations. Development, manufacture, filling,
assembly and packaging take place within Recipharm Group.

Top